masthead-news

News & Events

HTG Overview Video

HTG’s proprietary RNA technologies are designed to help better understand disease and treatment options for patients and to unlock a disruptive approach to drug discovery.

Read More

Posted on:
 

HTG Announces Recipients of Its 2020 HTG EdgeSeq Autoimmune Panel Research Grants

TUCSON, Ariz., July 23, 2020 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced Vinodh Pillai, M.D., Ph.D., Assistant Professor of Pathology and Laboratory Medicine at the Children’s Hospital of Philadelphia, and Thomas Dörner, MD, Professor of Rheumatology and Hemostaseology at Charité University Hospitals, Berlin, as award recipients of its 2020 HTG EdgeSeq Autoimmune Panel Research Grants.

Read More

Posted on:
 

An Interview with Institute of Oncology Research, Dr. Francesco Bertoni, MD

"The HTG EdgeSeq technology represents a nice way to combine the possibility of working with FFPE specimens and next-generation approaches.  Moreover, the HTG EdgeSeq Oncology Biomarker Panel (OBP) can be applied on in vitro models and then the results can be validated on FFPE specimens from clinical studies using the same assay." Dr. Bertoni, MD

Read More

Posted on:
 

Page last updated August 23, 2022